Edwards Lifesciences (EW)

Executive Summary

Edwards Lifesciences is a global leader in structural heart disease, most notably through its transcatheter aortic valve replacement (TAVR) portfolio. The company continues to innovate with next-generation valves and expansion into mitral and tricuspid therapies, addressing large unmet needs. In 2025, Edwards completed the spin-off of its critical care business, sharpening its focus on high-growth cardiovascular devices. Despite increasing competition from Medtronic and Abbott, the company maintains a dominant TAVR market share and a robust pipeline. Key growth drivers include the EVOQUE tricuspid system, which has demonstrated strong clinical outcomes, and the SAPIEN M3 mitral valve, targeting a sizable patient population. Edwards' strong balance sheet and commitment to R&D position it well for sustained leadership in the structural heart market.

Upcoming Catalysts (preview)

• Q3 2026FDA approval of EVOQUE tricuspid valve replacement system80% success
• Q4 2026Pivotal trial data readout for SAPIEN M3 transcatheter mitral valve60% success
• Q3 2026Update on China market access and TAVR reimbursement expansion70% success